ClinicalTrials.gg
RecruitingNCT04661215PSAGSUpdated Apr 3, 2026

Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms

An observational study in Gastroparesis, Idiopathic Gastric Motility Disorder and Diabetic Gastroparesis, sponsored by Johns Hopkins Bloomberg School of Public Health. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Johns Hopkins Bloomberg School of Public Health · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.

Planned enrollment
16th of 39
150 · median 108
Started
2026
with 8 others
Observational
39 of 184
17 open now
Primary completion
2027-03
later than 15 of 40 live
Registered
125th of 184
by date
Lead sponsor
9 of 184
Johns Hopkins Bloomberg School of Public Health

Among the 184 studies in Gastroparesis with a site in United States, this one is the 16th largest by planned enrollment of the 39 observational ones that give a count, is one of 9 that started in 2026, is one of 39 observational ones, reaches primary completion later than 15 of the 40 other live ones, and was the 125th registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Gastroparesis with a site in United States, or all of them as a file.
02

Study summary

The overall objective of this study is to determine if there are pyloric sphincter abnormalities in patients with gastroparesis symptoms and determine how prevalent these abnormalities are using tests to assess the pyloric sphincter - endoluminal functional luminal imaging probe (Endoflip™), water load satiety testing (WLST), and high-resolution cutaneous electrogastrography (HR-EGG) using Gastric Alimetry™ System.

Read the detailed description

Study Description: This is a multi-center, prospective, observational study to assess pyloric sphincter abnormalities in patients with symptoms of gastroparesis (both delayed and normal gastric emptying) and control participants without symptoms of gastroparesis using the commercially available, FDA approved endoluminal functional luminal imaging probe (Endoflip™) catheter, which measures diameter, cross-sectional area, pressure, compliance, and distensibility of gastrointestinal sphincter muscles.

This study will assess lower esophageal and pyloric sphincter diameter, CSA, pressure, distensibility, and compliance in patients with symptoms of gastroparesis and delayed gastric emptying, patients with symptoms of gastroparesis but with normal gastric emptying, and normal control participants. The protocol will also include a water load satiety test and use Gastric Alimetry™ System that assesses gastric myoelectrical activity in symptomatic participants but not control participants.

03

Conditions studied

  • Gastroparesis
  • Idiopathic Gastric Motility Disorder
  • Diabetic Gastroparesis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will be 150 adult men and women aged 18-85 years, located in the United States, 100 will have symptoms of gastroparesis, and 50 participants in the control group will be patients undergoing upper endoscopy for clinical evaluation of diarrhea, gastrointestinal (GI) bleed, or iron-deficiency anemia, or evaluation for bariatric surgery who do not have upper GI symptoms greater than 1 as assessed by the Gastroparesis Cardinal Symptom Index (GCSI) . Control group participants will not have Gastric Alimetry testing or water load satiety testing.

Eligibility criteria

Inclusion Criteria FOR SYMPTOMATIC PARTICIPANTS:

  1. Provision of signed and dated form.
  2. Stated willingness to comply with all study procedures and availability for the duration of the study.
  3. Male or female, aged 18-85
  4. Symptoms of gastroparesis, either diabetic or idiopathic etiology
  5. Symptoms of gastroparesis with minimum Gastroparesis Cardinal Symptom Index (GCSI) score of 2.0
  6. Individual will have had a prior 4-hour gastric emptying scintigraphy test performed for clinical evaluation within the last 6 months. This gastric emptying test would be done for clinical evaluation and is not part of the research study. From these participants with gastroparesis symptoms, we will include those with delayed gastric emptying as well as those with normal gastric emptying.
  7. Participant must not initiate any new treatments until completion of the study procedures.
  8. Willingness to:

    1. Stop histamine 2 antagonists, prokinetics (e.g., metoclopramide, erythromycin, domperidone, prucalopride), narcotics, anticholinergics, constipation medications (over the counter laxatives, isotonic polyethylene glycol (PEG) electrolyte preparations (e.g. MiraLax), prescription laxatives (e.g. lubiprostone), proton pump inhibitors, cannabinoids, and cannabidiol (CBD) for 3 days prior to each visit;
    2. Abstain from food and water after midnight (at least for 8 hours) before the start of each visit until after the visit.

INCLUSION CRITERIA FOR CONTROL PARTICIPANTS

  1. Provision of signed and dated informed consent form
  2. Male or female, aged 18 or older
  3. Undergoing an upper endoscopy for their clinical evaluation of diarrhea, GI bleed, or iron-deficiency anemia, or evaluation for bariatric surgery.
  4. Do not have upper GI symptoms greater than 1 as assessed by the Gastroparesis Cardinal Symptom Index (GCSI) of PAGI-SYM questionnaire.

EXCLUSION CRITERIA:

  1. Prior gut lumen surgery on the esophagus or the stomach, including Nissen fundoplication.
  2. Prior surgery on the pylorus (G-POEM, surgical pyloroplasty, surgical pyloromyotomy)
  3. Known history of achalasia or esophageal stricture
  4. Known history of physiological or mechanical GI obstruction
  5. Abnormalities seen on a prior upper endoscopy placing patient at increased risk:

    • Ulcer of the esophagus, stomach, or duodenum
    • Esophageal varices
  6. Individuals at risk for prolonging the endoscopy procedure: severe chronic pulmonary disease, severe food retention in the stomach on endoscopy.
  7. Presence of significant gastric or duodenal pathology that could be expected to cause dysmotility (e.g. significant inflammation, infiltrate disorders etc)
  8. Individuals with a history of other chronic disease potentially causative of gastrointestinal symptom
  9. Acute or chronic renal insufficiency
  10. Current eating disorders
  11. Females who are pregnant. A urine pregnancy test is routinely obtained on all females immediately prior to endoscopic procedures.
  12. Individuals with for endoscopy, including bleeding abnormalities
  13. Allergy to eggs preventing sedation with propofol and/or gastric emptying test
  14. Significant dysphagia
  15. Prior inflammatory bowel disease, Crohn's
  16. History of any esophageal/gastric/pyloric injection of botulinum toxin
  17. Patients on daily opioid use or >3 day/week use
  18. Use of glucagon-like peptide 1 (GLP1) receptor agonists or Sodium-Glucose Transport Protein 2 (SGLT2); Gastric inhibitory polypeptide (GIP)- glucagon-like peptide (GLP) combo
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Symptoms of gastroparesis

    Participants with symptoms of gastroparesis with minimum Gastroparesis Cardinal Symptom Index (GCSI) score of 2.0

  • Control participants

    Participants undergoing endoscopy for evaluation but without gastroparesis symptoms or gastroesophageal reflux symptoms. Score 1.0 or less (≤ 1 ) on the GCSI of Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) questionnaire

06

What researchers measure

Primary outcomes

  1. Distensibility of the pylorus

    Distensibility of the pylorus will be calculated as the median of three measurements (not three different inflations) of distensibility (mm2/mmHg) of the pylorus pressure using the Endoflip balloon catheter at 50 mL volume

    Time frame: Baseline

Secondary outcomes

  1. Opening diameter (mm) of the pylorus when 40 mL volume is introduced into the EF325N Endoflip™ measurement catheter.

    diameter (mm) of the pylorus

    Time frame: Baseline

  2. Opening diameter (mm) of the pylorus when 50 mL volume is introduced into the EF325N Endoflip™ measurement catheter.

    diameter (mm) of the pylorus

    Time frame: Baseline

  3. Cross Sectional Area(mm2) of the pylorus with 40 mL balloon volume

    Cross Sectional Area (mm2) of the pylorus

    Time frame: Baseline

  4. Cross Sectional Area(mm2) of the pylorus with 50 mL balloon volume

    Cross Sectional Area (mm2) of the pylorus

    Time frame: Baseline

  5. Compliance (mm3/mmHg) of the pylorus with 40 mL balloon volume

    Compliance (mm3/mmHg) of the pylorus

    Time frame: Baseline

  6. Compliance (mm3/mmHg) of the pylorus with 50 mL balloon volume

    Compliance (mm3/mmHg) of the pylorus

    Time frame: Baseline

  7. Pressure (mmHg) of the pyloric sphincter

    Pressure (mmHg) of the pyloric sphincter

    Time frame: Baseline

07

Study locations

5 of 5 sites recruiting
08

References and documents

Publications

  • Fisher R, Cohen S. Physiological characteristics of the human pyloric sphincter. Gastroenterology. 1973 Jan;64(1):67-75. No abstract available. PubMed 4683856 ↗
  • Parkman HP, Hasler WL, Fisher RS; American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004 Nov;127(5):1592-622. doi: 10.1053/j.gastro.2004.09.055. PubMed 15521026 ↗
  • Desipio J, Friedenberg FK, Korimilli A, Richter JE, Parkman HP, Fisher RS. High-resolution solid-state manometry of the antropyloroduodenal region. Neurogastroenterol Motil. 2007 Mar;19(3):188-95. doi: 10.1111/j.1365-2982.2006.00866.x. PubMed 17300288 ↗
  • Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology. 1986 Jun;90(6):1919-25. doi: 10.1016/0016-5085(86)90262-3. PubMed 3699409 ↗

Individual participant data

Plan to share: Yes — Public use complete database will be submitted to the NIDDK Data Repository

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: By the end of the funding period

Access criteria: Application through National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository; Institutional Review Board (IRB) approval

Data sharing details ↗ · repository.niddk.nih.gov

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 14 months after the start.

Of 47 observational studies under Gastroparesis, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 142. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2020
First posted
Dec 10, 2020
StartActual
Jan 13, 2026
Primary completionEst.
Mar 30, 2027
CompletionEst.
Apr 15, 2027
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04661215
Responsible party
Sponsor
First posted
Dec 10, 2020
Start date
Jan 13, 2026
Primary completion
Mar 30, 2027 (estimated)
Completion
Apr 15, 2027 (estimated)
Last update
Apr 3, 2026

Study contacts

Laura A Miriel, BS
Contact
laura.miriel@jhu.edu
410-955-4165
Emily Mitchell, MS, MBA
Contact
esharke5@jhu.edu
Pankaj Pasricha, MD
study chair · Mayo Clinic
Henry Parkman, MD
study chair · Temple University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion